Dawei Zhang

TL;DR: Using the CALL score model, clinicians can improve the therapeutic effect and reduce the mortality of COVID-19 with more accurate and reasonable resolutions on medical resources.

TL;DR: A higher degree of lymphopenia in various immune cell subsets as well as cytotoxicity and T cell inhibitory marker expression in severe cases compared with mild, indicate that immune-based targets for therapeutic interventions constitute a promising treatment for severe COVID-19 patients.

TL;DR: Evaluated data show that intravenous UC-MSCs infusion in patients with moderate and severe COVID-19 is safe and well tolerated, and phase 2/3 randomized, controlled, double-blinded trials with long-term follow-up are needed to evaluate the therapeutic use of UC- MSCs to reduce deaths and improve long- term treatment outcomes.

TL;DR: The epidemiological features are important for COVID-19 prophylaxis, including circulating interleukin-6 and lactateare independent prognostic factors, and CD8+ T cell exhaustion might be critical in the development of CO VID-19.